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PURPOSE. To analyze visual outcome, effectiveness of various modes of antibiotic treatment,
and prognostic factors in patients with serologically proven syphilitic uveitis.
METHODS. The clinical records of 85 patients (139 eyes) diagnosed with syphilitic uveitis
between 1984 and 2013 at tertiary centers in The Netherlands were retrospectively analyzed.
RESULTS. Mean age was 47 years (range, 27–73 years), 82.4% were male. HIV positivity was
found in 28 (35.9%) patients; 13 were newly diagnosed. Most patients had pan (45.9%) or
posterior (31.8%) uveitis. On average, logMAR visual acuity (VA) improved significantly from
0.55 at the start of syphilis treatment to 0.34 at 1 month and to 0.27 at 6 months follow-up.
Most patients (86.7%) reached disease remission. No differences in efficacy between the
various treatment regimens were found. A high logMAR VA at the start of syphilis treatment
and a treatment delay of more than 12 weeks were prognostic for a high logMAR VA at 6
months follow-up. Chronicity was not related to any form of treatment, HIV status, or
Venereal Disease Research Laboratory test outcome.
CONCLUSIONS. In this large cohort of 85 patients with syphilitic uveitis, visual outcomes were
favorable in the majority of cases. Visual outcome was dependent on VA at the start of syphilis
treatment and treatment delay.
Keywords: syphilis, uveitis, treatment outcome
Syphilis is caused by an infection with the bacteriumTreponema pallidum (T. pallidum) and classified as
acquired or congenital. As with other spirochete infections,
the clinical course of acquired untreated syphilis can be divided
into four different stages depending on the clinical manifesta-
tions.1 Syphilitic uveitis can occur in all stages except in the
primary stage.
Different tests are available for the diagnosis and staging of
syphilis. These include the so-called nonspecific tests like the
Venereal Disease Research Laboratory (VDRL) and Rapid
Plasma Reagin (RPR), which quantify the amount of serum
anticardiolipin antibodies by flocculation and T. pallidum
specific tests like the Fluorescent Treponemal Antibody
Absorption Test (FTA-ABS), T. pallidum particle agglutination
(TPPA), and T. pallidum haemagglutination assay (TPHA),
which measure the amount of serum antibodies specifically
directed against treponemal antigens.1 As was shown by
Grange et al.,2 newer PCR-based techniques have very low
sensitivity to detect syphilis in blood, and thus cannot replace
the above-mentioned serological tests.
The clinical presentation of ocular syphilis has been
described in many publications. It has been dubbed ‘‘The
Great Imitator’’ as it can mimic a wide range of ocular disorders.
The most common presentation of ocular syphilis is uveitis.
Before 1940, syphilis was the second cause of uveitis after
tuberculosis. With the introduction of penicillin and improved
diagnostics, syphilitic uveitis is a rare disease nowadays,
accounting for 1% to 2% of all uveitis patients.3 However, the
outcomes of the different serologic tests for syphilis can be
confusing, the optimal treatment of syphilitic uveitis is
debatable and it is unknown which factors will determine
visual prognosis.
To contribute to clarification of these aspects, we retro-
spectively evaluated visual outcomes in 85 patients with
syphilitic uveitis. Specifically, factors that correlated with a
worse visual prognosis or a chronic disease course were
investigated.
PATIENTS AND METHODS
Patients with a confirmed diagnosis of syphilitic uveitis between
1984 and 2013 at the University Medical Centers of Leiden (n¼
12), Groningen (n ¼ 19), Utrecht (n ¼ 33), the VU University
Medical Center Amsterdam (n ¼ 3), and the Rotterdam Eye
Hospital (n ¼ 18) were included. The diagnosis of syphilitic
uveitis was made in uveitis patients with positive results for
specific anti T. pallidum serologic tests (i.e., a positive TPPA or
TPHA and/or a positive FTA-ABS test) and agreement on the
diagnosis syphilitic uveitis between ophthalmologist, dermatol-
ogist, infectious disease specialist, and neurologist. In the above
centers, serologic testing for syphilis is part of the work-up in
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uveitis of unknown cause.4 This work-up depends on the
clinical presentation of the uveitis and may include blood tests
(e.g., erythrocyte sedimentation rate [ESR], C reactive protein
[CRP], hemoglobin [Hb], hematocrit [Ht], erythrocyte, throm-
bocyte and leukocyte counts, leukocyte differential, creatinine,
sodium, potassium, calcium, albumin, liver transaminases,
angiotensin converting enzyme, auto-antibodies, tests for
tuberculosis, and chest x-rays). Additional tests may be ordered
in special situations (e.g., anterior chamber fluid tests for
infectious uveitis). (Uveitis Guidelines Dutch Ophthalmic
Society, 2007).4 However, since all these centers are tertiary
referral centers, patients are often referred by ophthalmologists
working in general practices. A systematic work-up for uveitis
has not always been performed prior to referral. Medical records
were retrospectively analyzed. The study was conducted in
accordance with the Declaration of Helsinki and the study
design was evaluated by the Medical Ethical Committee of the
University Medical Center of Groningen who ruled that
approval was not required for this study.
All participating centers collect data on uveitis patients in a
database. However, the inclusion of patients started at different
time points at the different centers. Therefore, the inclusion
period varied per center (years are given between brackets):
Leiden University Medical Center (1985–2008), University
Medical Center Groningen (2001–2013), University Medical
Center Utrecht (1991–2011), VU University Medical Center
Amsterdam (2009–2012), and the Rotterdam Eye Hospital
(1996–2010).
The following data were recorded on an anonymized
standard entry form: sex, age at the start of syphilis treatment,
race, affected eye(s), interval between the date of onset of
uveitis symptoms and the date of final diagnosis of syphilitic
uveitis and initiation of antisyphilis treatment, laboratory data
including HIV status and the results of various serologic tests
for syphilis, the results of cerebrospinal fluid (CSF) analyses,
classification of the uveitis based upon standardization of
uveitis nomenclature (SUN) criteria,5 various clinical features,
treatment modalities, visual acuity (VA) in logarithm of the
minimal angle of resolution units (logMAR) at the start of
syphilis treatment, and at 1 and 6 months follow-up. The
Snellen VA was converted to logMAR VA for calculations. Visual
acuity at 1 and 6 months was analyzed in relation to type of
uveitis, treatment before syphilis treatment, interval between
uveitis and syphilis treatment, administration route of syphilis
treatment, HIV status, and immunosuppressive treatment
during syphilis treatment.
Uveitis was classified as anterior, intermediate, posterior, or
panuveitis. The presence of cystoid macular edema (CME) was
confirmed by fluorescein angiography (FA) or optical coher-
ence tomography (OCT). Retinitis, retinal ischemia, and
papillitis were diagnosed by FA. Serous retinal detachments
were diagnosed by fundoscopy or ultrasound (US). Fundoscopi-
cally observed retinal hemorrhages and retinal vasculitis were
recorded. Chronic uveitis was defined as persistent uveitis with
relapse within 3 months after discontinuing treatment5 or as an
active uveitis at 6 months follow-up.
The following treatment regimens were included: (1) benzyl
penicillin 0.15 million units/kg/d intravenously for 14 days; (2)
procaine penicillin 1.2 to 2.4 million units intramuscularly
during 10 to 17 days; and (3) oral doxycycline 200 mg twice
per day for 28 days or ceftriaxone intravenously 2 g/d for 14
days. Patients were divided into three groups based on the time
interval between presentation of uveitis and the start of syphilis
treatment. The first group received treatment within 4 weeks
after presentation of the uveitis, the second was treated within
4 to 12 weeks after presentation, and the third started
treatment after a 12-week interval.
Adjunctive treatment with corticosteroids (eye drops,
periocular injections, and systemic) and other immunosup-
pressives (systemic) was recorded. For statistical analyses,
three groups were made: (1) patients without adjunctive
treatment with steroids; (2) patients who received adjunctive
treatment with steroid eye drops; (3) a combined group of
patients (n ¼ 36) who received adjunctive treatment with
subconjunctival (n ¼ 4) or systemic corticosteroids (n ¼ 32).
Statistical analysis was performed by SPSS software version
20 (SPSS, Inc., Chicago, IL, USA). A P < 0.05 was considered
statistically significant. Analysis of VA improvement was done
by comparing VA at the start of syphilis treatment to that at 1
and 6 months by Friedman ANOVA with post hoc Wilcoxon
signed-rank test and Bonferroni correction. The Mann-Whitney
U test was used to test for statistical differences in VA at 1 and 6
months between the groups that were treated with local or
systemic corticosteroids and between HIV negative and
positive patients. The v2 test was used to test for relationships
between HIV status and anatomical location of the uveitis or
CSF abnormalities, respectively. A multiple linear regression
model was used to assess the weight and value of the
prognostic factors for visual outcome at 6 months.
RESULTS
Of the 89 patients classified as having syphilitic uveitis, a cohort
of 85 patients could be evaluated in detail, while four patients
were excluded because of lack of documentation. Patients’
characteristics are summarized in Table 1. As shown, only
patients with a positive TPHA or TPPA test were included. In
addition, VDRL testing was done in all patients, 69 (81.2%) of
whom were positive. Of the 16 VDRL negative patients, one
patient was HIV positive. Two patients had a documented
reinfection; they were both VDRL positive. FTA-Abs tests were
positive in all 43 tested patients. The majority of patients
(82.4%) were male and most (63.5%) had bilateral disease.
Lumbar punctures had been performed in 62 (72.9%) patients
(Table 1). Cerebrospinal fluid tested positive for TPHA or TPPA
in 33/57 (57.9%) patients, VDRL in 12/31 (38.7%) and FTA-Abs
in four out of six tested patients. In 28 (35.9%) patients, a HIV
coinfection was present. Of these, 15 (53.6%) had previously
been diagnosed with HIV, and 13 (46.4%) were newly
identified. No statistically significant relationship was found
between anatomical location of the uveitis, HIV status, and CSF
abnormalities.
Ocular features are shown in Table 2. In case of posterior
and panuveitis, optic nerve and retinal involvement and vitritis
probably explain the low VA at presentation. Visual field defects
at any moment during follow-up were found in 44 out of 52
(84.6%) tested eyes. These were predominantly eyes with
posterior (n¼ 14, 31.8%) or panuveitis (n¼ 22, 50%).
In Tables 3 and 4, the logMAR VA per eye at the start of
syphilis treatment and at 1 and 6 months is shown. On average,
a statistically significant improvement in VA was observed at 1
and 6 months as compared to VA at start of syphilis treatment.
Most patients were treated with intravenous (IV) benzyl
penicillin G (n ¼ 55, 64.7%) or ceftriaxone (n ¼ 2, 2.4%) for 2
weeks (Table 4). Intramuscular (IM) treatment with procaine
penicillin was given in 15 (17.6%) patients, 5 (5.9%) patients
were treated with oral antibiotics (doxycycline in all cases), and
8 (9.4%) patients were treated with a combination of IV, IM, and
oral treatment.
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Only in patients treated by IV antibiotics, a statistically
significant VA improvement at 6 months (as compared to VA at
start of treatment) was seen (Table 4). Patients treated with
antibiotics by different routes of administration also had VA
improvement at 6 months, but this was not statistically
significant (Table 4). Sixty-seven patients (78.8%) received
systemic, subconjunctival, or local steroids next to antibiotic
treatment. No statistically significant difference in VA at 6
months was found between patients who had versus those who
had not received any adjunctive treatment with systemic or
local steroids (P ¼ 0.691). No cases of Jarisch-Herxheimer
reaction were reported.
Table 5 displays the course of the disease after treatment.
Ten (13.5 %) patients developed chronic uveitis. Chronicity was
not related to the duration of treatment delay, any form of
treatment, or outcome of VDRL testing.
With Friedman ANOVA statistical analysis, we evaluated VA
outcomes at 1 and 6 months when compared to VA at the start
of syphilis treatment. Delayed treatment in itself was associated
with less VA improvement at 6 months. Whether patients had
received any form of treatment not specifically directed at
syphilis as compared to no treatment prior to the start of
specific treatment directed at syphilis, did not seem to affect VA
outcomes at 1 and 6 months (Table 4). Prior treatment
regimens differed and consisted of antivirals (n ¼ 10) or
antibiotics/antitoxoplasmosis drugs (n¼ 13).
By using a multivariate linear regression model, we analyzed
which factors were associated with the outcome variable
logMAR VA at 6 months. Within this model, we took into
account: the type of uveitis, delay between onset of uveitis and
treatment, bilateral disease, ethnicity, VDRL test results, route
of administration of treatment, HIV positivity, treatment before
syphilis treatment, the use of corticosteroids or other steroid-
sparing immunosuppressive drugs, and VA at the start of
syphilis treatment. Regarding VDRL status, the statistical
analysis in this regression model was done in two ways. The
first analysis was done with the VDRL negative versus the VDRL
positive patients. The second analysis was done with the VDRL
positive patients versus the combined VDRL negative patients
and patients with a low VDRL titer (below 1:8). With this
model, we found that a lower VA at the start of syphilis
treatment (P < 0.001) and a delay of more than 12 weeks
between presentation and treatment for syphilis (P ¼ 0.038)
TABLE 1. Patient Characteristics, N ¼ Patients
N (%)
Syphilitic uveitis






Serological tests for syphilis
TPHA/TPPA positive 85/85 (100)
VDRL positive 69/85 (81.2)
FTA-Abs positive 43/43 (100)
Lumbar puncture findings
Performed lumbar punctures 62/85 (72.9)
Positive TPHA/TPPA 33/57 (57.9)
Positive VDRL 12/31 (38.7)
Positive FTA-Abs 4/6 (66.7)
HIV status
HIV positive 28/78 (35.9)
Already known 15/28 (53.6)
Newly diagnosed 13/28 (46.4)
Interval uveitis and syphilis treatment
<4 wk 36/85 (42.4)
4–12 wk 16/85 (18.8)
>12 wk 33/85 (38.8)




Combination of the above 8/85 (9.4)
The fraction (x/y) displays the number of patients with a specific
characteristic (x) in relation to the total number of patients evaluated
(y).
* Surinam Blacks, n ¼ 7; African Americans, n ¼ 2; Asians, n ¼ 7;
Surinam Indians, n ¼ 2.
TABLE 2. Ocular Features
Anterior Uveitis
Intermediate
Uveitis Posterior Uveitis Panuveitis Sclero-Uveitis Total, n
Number of patients 14 2 27 39 3 85
Visual acuity at presentation
>20/50 10 2 8 15 0 35
20/200–20/50 2 0 7 13 3 25
>NLP–20/200 2 0 12 11 0 25
NLP 0 0 0 0 0 0
Number of affected eyes 22 4 42 66 5 139
Vitritis 3 4 18 55 5 85
Cystoid macular edema 2 0 9 20 1 32
Retinitis 0 0 31 50 5 86
Retinal ischemia 0 0 10 20 1 31
Retinal hemorrhages 0 0 14 22 4 40
Retinal vasculitis 0 0 17 30 3 50
Papillitis 0 2 31 39 2 74
NLP, no light perception.
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were associated with a statistically significantly worse visual
outcome at 6 months. These two variables explain 34.6% (R2¼
0.346) of the variance in VA outcomes at 6 months.
To correct for the possible bias of systemic treatment in a
mixed population of bilateral and unilateral disease, we took
bilateral disease into account in the regression model and we
added Table 6. Bilateral disease did not influence the visual
outcome at 6 months (P ¼ 0.216).
Table 7 shows the characteristics of the six patients (10
eyes) with visual loss at 6 months. Posterior uveitis was the
predominant type of uveitis associated with visual loss. Optic
neuropathy, subretinal fibrosis, retinal detachment, and
glaucoma were the main causes of severely reduced VA in
these patients. In one patient with hand motion VA, the
posterior segment could not be evaluated due to severe
persistent anterior segment inflammation (hypopyon; this
patient refused intensive local treatment).
DISCUSSION
Within this cohort of 85 patients with serologically proven
syphilitic uveitis, the overall visual prognosis was good if
timely and adequate therapy was given. High logMAR VA (low
Snellen VA) outcomes were associated with a treatment delay
of more than 12 weeks, and high logMAR VA at the start of
syphilis treatment. A statistically significant improvement of
VA at 1 and 6 months as compared to that at the start of
syphilis treatment was observed in patients treated with IV
antibiotics, and in those that received adjunct corticosteroids.
Absolute values of logMAR VA at 6 months were not associated
with the route of administration of antibiotics, treatment with
corticosteroids, and HIV status. The majority of patients had
one uveitis episode, but chronic uveitis developed in 13.5%.
None of the evaluated factors was associated with a chronic
course.
Overall, a good visual prognosis in our study is supported
by the finding that the 117 eyes included in the per eye
analysis showed a statistically significant improvement at 1 and
6 months follow-up. Also, 16 of the 22 eyes (72.7%) with
missing data at 6 months had a Snellen VA above 20/32
(logMAR 0.2) at 1 month follow-up. Therefore, we may assume
an even more favorable prognosis than that presented in our
tables. An overall good visual prognosis in syphilitic uveitis
such as found in this large cohort confirms previous
studies.6–11 In our study, a higher logMAR VA at the start of
syphilis treatment and a delay of more than 12 weeks between
the first presentation of uveitis and treatment for syphilis were
associated with a statistically significantly higher logMAR VA at
6 months. Possible reasons for diagnostic delay include
patients’ and doctors’ delay. It is hard to reduce the former,
whereas the latter can be minimized by following the general
advice to test for syphilis in patients with uveitis of unknown
origin.1,12,13
Treatment Outcome
Probably, delayed treatment is associated with irreversible
structural damage.1,7,14,15 This is supported by the association
between high logMAR VA at the start of syphilis treatment and
at 6 months. Worsening of VA during follow-up occurred in 10
eyes and was associated with structural damage to the optic
disc and retina. In our study, the majority of patients were
treated with intravenous penicillin (Table 4). Smaller numbers
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These different treatment modalities were not prognostic for a
higher logMAR VA at 6 months.
Previous studies on prognostic factors in ocular syphi-
lis6,16,17 showed no difference in visual outcome when
comparing the ‘‘classic’’ regimen of intravenous penicillin with
other antibiotics. But, these studies6,16,17 were all in small
groups, with different kinds of antibiotics and therefore the
results should be interpreted cautiously.
Corticosteroids
Another finding in our study is that patients who received
local, subconjunctival, or systemic corticosteroids next to
antibiotic treatment for syphilis had on average a statistically
significant improvement in VA at 1 and 6 months, when
compared to VA at the start of syphilis treatment. The absence
of a statistically significant difference between patients treated
with additional oral steroids or steroid injections versus those
not treated in this way seems to indicate that additional
steroids may be ineffective. However, the fact that mean
logMAR VA at the start of syphilis treatment was higher in
patients receiving additional oral steroids or steroid injections
than in patients not receiving this (Table 4) indicates that
adjunct corticosteroid treatment may have been preferably
given to the more severe cases. Since logMAR VA outcomes in
these possibly more severe cases are similar to outcomes in
the probably less severe groups (Table 4), a beneficial effect of
adjunct corticosteroid treatment cannot be excluded. Some
authors have reported on their clinical experience with
corticosteroids in ocular syphilis18,19 but on a smaller scale
and not at set time points. Previous studies advised local
corticosteroids in case of interstitial keratitis or anterior
uveitis14,20 and systemic corticosteroids in case of profound
visual loss, posterior uveitis,21 scleritis, and optic neuritis.14,20
Because of our results and recommendations in the literature,
we suggest considering adding corticosteroids to antibiotic
treatment in all cases of syphilitic uveitis. The use of oral
corticosteroids is also considered beneficial in preventing a
Jarisch–Herxheimer reaction.20,22 The use of corticosteroids
without antibiotic treatment, though not associated with
worse VA outcomes at 6 months in our study, may aggravate
syphilitic uveitis. Zamani and Garfinkel23 published a case
report on a patient who developed yellow placoid chorioret-
inal lesions during treatment with oral corticosteroids, which
disappeared after their discontinuation.
HIV
In our study, HIV positivity was found in 28 patients, 13 of
whom were newly diagnosed. This re-emphasizes the risk of
coinfection with other sexually transmitted diseases in this
patient group, and the desirability to test for HIV in case of
ocular syphilis. Previously, HIV positivity has been associated
with a worse visual outcome in syphilitic uveitis, a finding we
and other recent studies9–11,24,25 could not confirm. Also,
previous studies described that HIV-positive patients tended to
have a higher proportion of posterior and panuveitis and
neurosyphilis than HIV-negative patients. In contrast, we did
not find statistically significant associations between HIV
positivity, anatomical location of the uveitis, and CSF abnor-
malities. Differences between our outcomes and those in
previous studies may be due to an improved immune-status of
HIV-positive patients because of highly active antiretroviral
therapy (HAART).26,27 In line with this, current IUSTI
guidelines1,12,13 state that HIV coinfected syphilitic patients
should be treated as immunocompetent patients, except for
those who have CD4þ cell counts of  350/lL.
Clinical Presentation
Our study confirms previous reports6,7,16,28,29 that ocular
syphilis occurs predominantly in men. Further, it confirms that
syphilitic uveitis is a variable condition with a high diversity of
clinical features. It can be uni- or bilateral, all anatomical
locations may be affected, and it may run an acute or chronic
course. In our study, bilateral uveitis was seen in 63.5%,
whereas posterior (n ¼ 27, 31.8%) and panuveitis (n ¼ 39,
45.9%) were far more often present than anterior uveitis (n ¼
14, 16.5%). This is in line with recent articles,6,7,16,24 but it
differs from some older studies that observed uveitis to be
located mainly anteriorly.30,31
TABLE 5. Administration Route Syphilis Treatment, N¼ Patients
Administration Route
Syphilis Treatment N (%)
Remission at
6 mo, N (%)*
Chronic at
6 mo, N (%)
Total 85/85 65/75 (86.7) 10/75 (13.3)
Intravenous 57/85 (67.1) 44/57 (77.2) 7/57 (12.2)
Intramuscular 15/85 (17.6) 11/15 (73.3) 2/15 (13.3)
Oral 5/85 (5.9) 5/5 0
Combination
of the above 8/85 (9.4) 5/8 (62.5) 1/8 (12.5)
* In 10 patients, data regarding disease status at 6 months was
missing.
TABLE 6. Best Eye Analysis (logMAR Acuity per Eye)
Ocular Syphilis VA at Presentation VA at 1 mo VA at 6 mo
VA Difference
1 and 6 mo*
All eyes, n ¼ 139 (139/139) 0.55 (SD 0.66) (134/139) 0.34 (SD 0.6) P ¼ 0.001† (117/139) 0.27 (SD 0.51) P ¼ <0.001‡ P ¼ <0.001
Unilateral eyes, n ¼ 31 (31/31) 0.71 (SD 0.77) (31/31) 0.4 (SD 0.55) P ¼ 0.003† (26/31) 0.25 (SD 0.4) P ¼ <0.001‡ P ¼ 0.002
Bilateral best eye and
unilateral eyes, n ¼ 85 (85/85) 0.39 (SD 0.58) (83/85) 0.22 (SD 0.47) P ¼ <0.001† (72/85) 0.15 (SD 0.33) P ¼ <0.001‡ P ¼ <0.001
To correct for the bias of systemic therapy in bilateral versus unilateral disease, we performed VA analyses at the various time points for all eyes,
unilateral eyes only, and bilateral best eyes plus unilateral eyes. At each time point, the fraction (x/y) displays the number of eyes with a specific
characteristic (x) in relation to the total number of evaluated eyes (y). The results of all analyses show a significant improvement of VA between all
time points and in all analyzed groups.
* Friedman ANOVA with post hoc Wilcoxon signed-rank between VA at 1 month and 6 months.
† Friedman ANOVA with post hoc Wilcoxon signed-rank test between presentation and 1 month.
‡ Friedman ANOVA with post hoc Wilcoxon signed-rank between presentation and 6 months.
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VDRL Test Outcome
VDRL test results give some information on the duration and
activity of the infection and they can be used to monitor the
response to treatment. The interpretation of the VDRL test is
sometimes difficult and debatable. A VDRL test becomes
positive 4 to 5 weeks after infection, but it can sometimes be
negative due to the prozone phenomenon.1 Next to that, in
20% to 30% of the patients the test becomes negative over
time.32 Therefore, a negative VDRL test result does not rule out
the diagnosis of syphilitic uveitis.10 A previous study reported
that HIV positivity may be associated with higher than
expected VDRL serologic titers, false-negative serologic results,
and delayed appearance of sero-reactivity.32 These findings
were not confirmed within our study. Also, we did not observe
an effect of VDRL test outcome on VA at 6 months in the
multivariate linear regression model. Neither did we find a
difference in chronicity at 6 months between VDRL-negative or
positive patients.
Antibiotic Treatment
According to the European guidelines, the gold standard for the
treatment of syphilitic uveitis is IV benzyl penicillin 12 to 24
million units daily, given in 3 to 4 million units doses every 4
hours for 10 to 21 days.1,12,13 In special situations (pregnancy,
allergy, or refusal of intravenous treatment), oral or intramus-
cular treatment can be considered. Improvement in VA at 1 and
6 months was seen in all groups of patients independent of the
route of administration of antibiotics. Based upon the multiple
linear regression model, the group of patients treated with IV
penicillin showed a tendency toward a somewhat better VA
result. The absence of a statistically significant difference in this
model may probably be explained by the modest sizes of the
non-IV treated groups. A similar argument may apply to the
absence of an effect of route of administration on the
development of chronic uveitis. At present, the results of our
study support the current guidelines on treatment for ocular
syphilis.
Strengths and Limitations of the Study
The strengths of this study are its relatively large study
population, the systematic way in which data were collected,
and its adherence to the SUN classification system and
guidelines for publications. The limitations of this study are
its retrospective nature, and its long inclusion period. The latter
may theoretically have influenced treatment strategies. How-
ever, the mainstay of syphilis treatment is penicillin, and this
has not changed over the past decades. Some statistically
significant relations may have been missed because of small
numbers of patients in some subgroups. Also, the study was
conducted in tertiary uveitis centers, and therefore, this
population may not represent the total spectrum of syphilitic
uveitis. Personal experience and preferences of ophthalmolo-
gists may have influenced their choice of treatment. Despite
this, we feel that the study results can contribute to optimum
care for patients with syphilitic uveitis.
CONCLUSIONS
Overall, VA outcomes in syphilitic uveitis are good. A low VA at
the start of syphilis treatment and treatment delay of more than
12 weeks results in a less favorable visual prognosis. To shorten
this delay, low threshold testing for syphilis should be done in
uveitis of unknown cause. Intravenous benzyl penicillin is an
effective treatment for syphilitic uveitis. It is not clear whether
adjunct steroid treatment is beneficial. Structural damage to the
optic nerve and retina are the main causes of permanent visual
loss.
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